SCHEMBL17129341

SCHEMBL17129341

COC(=O)c1ccc(COc2ccc(B3OC(C)(C)C(C)(C)O3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.59
SMN1; SMN2 Q16637 6/20 0.59
NPC1 O15118 5/20 0.59
MAPT P10636 5/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
LMNA P02545 2/20 0.50
HIF1A Q16665 1/20 0.49
DGAT1 O75907 1/20 0.49
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
POLB P06746 1/20 0.47
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
FFAR1 O14842 1/20 0.46
PKM P14618 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17129163 0.86 MRGPRX4 (0.61) RAB9ASMN1; SMN2NPC1LMNAHIF1A
SCHEMBL105161 0.85 CA1 (0.50) RAB9ASMN1; SMN2NPC1MAPTDGAT1
SCHEMBL6228298 0.85 MAPT (0.61) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL2187091 0.84 CA1 (0.49) RAB9AMAPTMEN1KMT2AHIF1A
SCHEMBL9985664 0.83 CA1 (0.54) RAB9ASMN1; SMN2NPC1LMNAHIF1A
SCHEMBL2267580 0.83 DGAT1 (0.56) RAB9ASMN1; SMN2NPC1DGAT1POLB
SCHEMBL11350421 0.82 RAB9A (0.82) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL10236929 0.82 RAB9A (0.82) RAB9ASMN1; SMN2NPC1MAPTMEN1
SCHEMBL17129555 0.82 DGAT1 (0.51) MAPTHIF1ADGAT1ALDH1A1CA1
SCHEMBL15981216 0.81 DGAT1 (0.55) HIF1ADGAT1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10280170-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-05-07 US disclosed
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-22 US disclosed
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-22 US disclosed
WO-2015144799-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280170-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors ROS1, NOX1, NOX5 RAB9A 682/4885SMN1; SMN2 4001/4885NPC1 835/4885
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS ROS1, NOX1, NOX5 RAB9A 682/4885SMN1; SMN2 4001/4885NPC1 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.